NCT05675410 2026-03-19
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
9 trialsNCT02166463 2026-03-18
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04404283 2026-03-17
ECHELON-3
Seagen Inc.
Phase 3 Active not recruiting
NCT01712490 2026-02-27
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda
Phase 3 Completed
NCT02684292 2026-02-18
MK-3475-204
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04685616 2026-02-18
RADAR
University College, London
Phase 3 Recruiting
NCT03907488 2025-12-04
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT07258680 2025-12-02
BrEto-TCL
N.N. Petrov National Medical Research Center of Oncology
Phase 3 Enrolling by invitation
NCT07178457 2025-09-17
BeCALM
Assistance Publique - Hôpitaux de Paris
Phase 3 Not yet recruiting